Developing countries that seek to implement compulsory licensing face a crucial dilemma—between greater innovation and greater access. As long as inadequate and inequitable mechanisms to stimulate health research and development (R&D) exist, developing countries should be extremely cautious in undertaking measures, such as compulsory licensing, that could be detrimental to the development of new drugs.